Literature DB >> 19265157

TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response.

Kai Yang1, He-Xin Shi, Xin-Yi Liu, Yu-Fei Shan, Bo Wei, She Chen, Chen Wang.   

Abstract

Virus infection induces host antiviral responses including induction of type I IFNs. Transcription factor IFN regulatory factor 3 (IRF3) plays an essential role and is tightly regulated in this process. Herein we report that TRIM21 (tripartite motif-containing 21) is significantly induced and interacts with IRF3 upon RNA virus infection. Ectopic expression or knockdown of TRIM21 could respectively enhance or impair IRF3-mediated gene expression. Mechanistically, TRIM21 interferes with the interaction between Pin1 (peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1) and IRF3, thus preventing IRF3 ubiquitination and degradation. A conserved motif in the B 30.2 domain of TRIM21 is critical for its modulation of IRF3 function, while the RING finger is dispensable. Host antiviral responses are significantly boosted or crippled in the presence or absence of TRIM21. Our results identify TRIM21 as an essential modulator of IRF3 stability and demonstrate that it positively regulates the strength and duration of primary antiviral response, thus further strengthening the notion that the TRIM family is evolutionarily integrated with innate immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265157     DOI: 10.4049/jimmunol.0803126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

Review 1.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

Review 2.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

3.  Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production.

Authors:  Jennifer A Young; Decha Sermwittayawong; Hee-Jung Kim; Suruchi Nandu; Namsil An; Hediye Erdjument-Bromage; Paul Tempst; Laurent Coscoy; Astar Winoto
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

Review 4.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

5.  Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts.

Authors:  Ryusuke Yoshimi; Tsung-Hsien Chang; Hongsheng Wang; Toru Atsumi; Herbert C Morse; Keiko Ozato
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

6.  TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3β to TBK1.

Authors:  Yunfei Qin; Qingxiang Liu; Shuo Tian; Weihong Xie; Jun Cui; Rong-Fu Wang
Journal:  Cell Res       Date:  2016-02-26       Impact factor: 25.617

7.  Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation.

Authors:  Nathaniel Sears; Ganes C Sen; George R Stark; Saurabh Chattopadhyay
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

8.  Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?

Authors:  Caroline Jefferies; Claire Wynne; Rowan Higgs
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

Review 9.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

10.  Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.

Authors:  N C Kyriakidis; E K Kapsogeorgou; V C Gourzi; O D Konsta; G E Baltatzis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.